31 results about "Cpg oligonucleotides" patented technology

The invention relates to methods for regulating hematopoiesis using CpG containing oligonucleotides. In particular, the invention relates to methods of treating thrombopoiesis and anemia by regulating hematopoiesis. The invention also relates to methods of regulating immune system remodeling by administering CpG oligonucleotides to control hematopoiesis.

The present invention provides a CpG oligonucleotide prodrug that includes a thermolabile substituent on at least one nucleotide thereof. The present invention also provides compositions that include a carrier and a therapeutically effective amount of at least one CpG oligonucleotide prodrug. The present invention further provides therapeutic methods of using such thermolabile CpG oligonucleotide prodrugs and compositions thereof. The present invention further provides a method of inhibiting tetrad formation in a CpG oligonucleotide by functionalizing the CpG oligonucleotide with one or more thermolabile substituents.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Pharmaceutical compositions are provided that include an antibiotics, but that include ingredients that counteract the effect of that antibiotic on wound healing, without altering the bactericidal properties of the antibiotic. These pharmaceutical compositions include an effective amount of 1) an imidazoquinoline having toll-like receptor 7 (TLR7) ligand activity, 2) an immunostimulatory K-type CpG oligodeoxynucleotide (ODN) comprising an unmethylated CpG motif, 3) an antibiotic, and 4) a surfactant, wherein the composition is formulated for topical administration. Methods for accelerating wound healing are also provided. These methods include topically administering the disclosed compositions. The wound can be in the skin or in the eye.

Specific CpG oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and from patients suffering from CLL or FL. The compounds are also preferably used in combination with a cancer therapy chosen among radiation treatment, hormone treatment, surgical intervention, chemotherapy, immunological therapies, photodynamic therapy, laser therapy, hyperthermia, cryotherapy, angiogenesis inhibition, or a combination of any of these, and is most preferably an immunological treatment and comprises the administration of an antibody to the patient.

The invention provides a method for preparing an antigen composition capable of targeting glioma cells and glioma stem cells. The method comprises the steps of (1) providing isolated cell populations containing the glioma stem cells and the glioma cells; (2) amplifying the glioma stem cells in the cell populations; (3) carrying out freeze-thaw cracking treatment on the amplified cell populations so as to obtain the antigen composition containing glioma stem cell lysates and glioma cell lysates. The invention also provides a vaccine containing the antigen composition, dendritic cells and CpG oligodeoxynucleotide, and application of the vaccine in preparation of medicines for treating glioma. The antigen composition and the vaccine which are provided by the invention can target the glioma cells and the glioma stem cells at the same time, thus being capable of effectively killing the residue glioma stem cells and the glioma cells and further inhibiting the recurrence of the glioma.

The invention provides a CpG nucleic acid medicine conveying system. The CpG nucleic acid medicine conveying system comprises a carrier and a CpG nucleic acid medicine, and is characterized in that the carrier is an aldehyde group silane coupling agent modified mesoporous silica nano grain; the CpG nucleic acid medicine is 5' terminal amino modified CpG oligonucleotide; the carrier and the CpG nucleic acid medicine are in covalent linkage through an imine linkage; and the imine linkage has pH sensitivity. The invention further provides a preparation method of the CpG nucleic acid medicine conveying system. According to the CpG nucleic acid medicine conveying system provided by the invention, the carrier and the CpG nucleic acid medicine are in covalent linkage through the pH sensitive imine linkage and can reach a lysosome after being absorbed by immune cells; and the free CpG nucleic acid medicine is released under a weak acidic condition of the lysosome, so that the immune cells are induced to secrete a series of cell factors. The CpG nucleic acid medicine conveying system can realize controllable release of the CpG nucleic acid medicine and has high secretion induction efficiency.

Provided herein are methods for producing stimulated populations of regulatory B cells comprising treating an isolated population of B cells with stimulatory agents, such as CpG oligonucleotides, BCR ligation, and CD40 ligand. Also provided herein are methods of treating immune disorders, such as chronic graft versus host disease, with the stimulated population of regulatory B cells.

The present invention provides a method for treating infectious disease exacerbated asthma, comprising administering an effective amount of a CpG oligonucleotide to an asthmatic individual, particularly the infectious disease exacerbated asthma may be virus exacerbated asthma.

Pharmaceutical compositions comprising a CpG oligonucleotide, a buffer agent, and one or more salts having a total salt concentration of about 80-130 mM. A majority population of the CpG oligonucleotides in the composition is in dimeric form. Also provided herein are uses of the pharmaceutical compositions for modulating immune responses in subjects in need of the treatment, for example, cancer patient.